Virios Therapeutics, Inc. (VIRI): Price and Financial Metrics


Virios Therapeutics, Inc. (VIRI): $4.32

0.13 (+3.10%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VIRI to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

VIRI Stock Price Chart Interactive Chart >

Price chart for VIRI

VIRI Price/Volume Stats

Current price $4.32 52-week high $7.45
Prev. close $4.19 52-week low $3.30
Day low $4.24 Volume 1,800
Day high $4.47 Avg. volume 20,653
50-day MA $4.35 Dividend yield N/A
200-day MA $5.16 Market Cap 35.99M

Virios Therapeutics, Inc. (VIRI) Company Bio


Virios Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of antiviral therapies to treat diseases associated with a viral triggered abnormal immune response including fibromyalgia. It offers IMC-1 a novel, proprietary, fixed dose combination of famciclovir and celecoxib. The company was founded by William L. Pridgen on February 28, 2012 and is headquartered in Alpharetta, GA.


VIRI Latest News Stream


Event/Time News Detail
Loading, please wait...

VIRI Latest Social Stream


Loading social stream, please wait...

View Full VIRI Social Stream

Latest VIRI News From Around the Web

Below are the latest news stories about Virios Therapeutics Inc that investors may wish to consider to help them evaluate VIRI as an investment opportunity.

A Fireside Chat with Greg Duncan - CEO of Virios Therapeutics

NASDAQ:VIRI Richard Hantke: Hello everyone. My name's Richard Hantke. I'm with Zacks Small Cap Research, and welcome to the first in a new series of fireside chats. I am here with Greg Duncan, Chairman and CEO of Virios Therapeutics (NASDQ:VIRI). Hi Greg. Greg Duncan: Very nice to see you Richard. Richard Hantke: Zacks Small Cap Research is a division of Zacks Investment Research, and we focus on

Yahoo | February 1, 2022

RedChip Partners with Benzinga to Host Exclusive Small-Cap CEO Interview Series on January 28

ORLANDO, FL / ACCESSWIRE / January 26, 2022 / RedChip Companies, Inc., an international investor relations, media, and research firm focused on microcap and small-cap companies, is pleased to announce its partnership with Benzinga to host an exclusive series of CEO interviews on January 28, beginning at 9:15 a.

Yahoo | January 26, 2022

Virios Therapeutics to Present at the Virtual H.C. Wainwright BioConnect Conference

ATLANTA, January 04, 2022--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that Greg Duncan, Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright BioConnect Conference, which is taking place virtually January 10 - 13, 2022.

Yahoo | January 4, 2022

Gregory Scott Duncan Acquires 5,000 Shares of Virios Therapeutics, Inc. (NASDAQ:VIRI) Stock

Virios Therapeutics, Inc. (NASDAQ:VIRI) CEO Gregory Scott Duncan acquired 5,000 shares of Virios Therapeutics stock in a transaction dated Tuesday, December 21st. The shares were acquired at an average price of $5.52 per share, with a total value of $27,600.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is []

Transcript Daily | December 24, 2021

Virios Therapeutics, Inc. (NASDAQ:VIRI) CEO Acquires $27,600.00 in Stock

Virios Therapeutics, Inc. (NASDAQ:VIRI) CEO Gregory Scott Duncan acquired 5,000 shares of Virios Therapeutics stock in a transaction dated Tuesday, December 21st. The shares were acquired at an average price of $5.52 per share, with a total value of $27,600.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is []

Dakota Financial News | December 24, 2021

Read More 'VIRI' Stories Here

VIRI Price Returns

1-mo 7.73%
3-mo -23.67%
6-mo -20.73%
1-year -17.71%
3-year N/A
5-year N/A
YTD -15.54%
2021 -31.89%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6253 seconds.